$AUTL Trend Reversal - LONG
8M Float
8% Short
$386 M market cap
Offering complete Feb 12
Looks like AUTL may be breaking out of it's downtrend soon. I picked up a position on Feb 12.
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics today and set a price target of $18.00. The company’s shares closed last Friday at $7.29.
According to TipRanks.com, Goldstein is a 5-star analyst with an average return of 19.4% and a 43.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $16.20. (source: smarteranalyst.com/new-blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-autolus-therapeutics-autl-denali-therapeutics-dnli-and-viatris-vtrs/)
8% Short
$386 M market cap
Offering complete Feb 12
Looks like AUTL may be breaking out of it's downtrend soon. I picked up a position on Feb 12.
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics today and set a price target of $18.00. The company’s shares closed last Friday at $7.29.
According to TipRanks.com, Goldstein is a 5-star analyst with an average return of 19.4% and a 43.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $16.20. (source: smarteranalyst.com/new-blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-autolus-therapeutics-autl-denali-therapeutics-dnli-and-viatris-vtrs/)
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.